The Sanders Firm is Assigned the First Fosamax Trial by prweb

VIEWS: 9 PAGES: 2

									The Sanders Firm is Assigned the First Fosamax Trial
The FDA issues another warning concerning the osteoporosis drug Fosamax as The Sanders
Firm prepares for the first jury trial against the pharmaceutical giant Merck.
Mineola, NY (PRWEB) March 15, 2010 -- The United States Food and Drug Administration, via its website at
FDA.gov, has issued a “FDA Drug Safety Communication” about the common osteoporosis drug Fosamax©, and
others of its class, concerning an increased incidence of femur fractures in women. The FDA’s statement is part of
its ongoing investigation as to the safety and efficacy of these drugs in osteoporosis sufferers who are already at
an increased risk of bone disorders. This is more bad news for the manufacturer of Fosamax, global
pharmaceutical giant Merck and comes as the first of thousands of lawsuits alleging that the drug causes a rare
jaw disorder is set for trial in New Jersey with The Sanders Firm representing the victim.



 The Atlantic County Superior Court of New Jersey has set the first jury trial (Docket No. ATL-L-3644-08)
concerning Fosamax for July 12, 2010, with the case meant to serve as a “bell-weather” for thousands of others
pending before the court. The plaintiff is an osteoporosis sufferer that used the drug for approximately 4 years
before she developed severe osteonecrosis of the jaw, a debilitating side-effect suffered by thousands of other
women who used Fosamax. Osteonecrosis of the jaw is the permanent death of living bone tissue that requires
extensive treatment to correct and causes considerable pain and disfigurement.

 Marc Grossman of The Sanders Firm, a New York attorney that represents the plaintiff in the bell-weather case,
as well as hundreds of former Fosamax users, states, “We are ready and eager to have our day in court and hold
Merck responsible for the suffering it caused to thousands of women. Merck marketed this drug as a treatment for
osteoporosis, when it knew the drug caused the death of bone tissue in the jaw. It’s a blatant example of the drug
industry putting increased profits before the safety of people.”

 Fosamax belongs to a class of drugs called biphosphonates and is the most widely prescribed of the class. In
2005, Merck succumbed to increasing pressure from the Food and Drug Administration and the medical
community to add a warning on the Fosamax label that osteonecrosis of the jaw was a known risk of the drug. In a
January, 2009 article published in the Journal of the American Dental Association, several dentists from the
University of Southern California have recommended that all dental professionals warn their patients that
''Because you are taking a type of drug called bisphosphonate, you may be at risk for developing osteonecrosis of
the jaw and certain dental treatment may increase that risk.''

 Marc Grossman is a Senior Partner at The Sanders Firm, a National Law Firm with almost fifty attorneys,
one-hundred and twenty staff members and clients in all fifty States. For the past forty-three years, The Sanders
Firm has successfully represented thousands of victims of defective drugs and products and has recovered over
$500 Million for its clients. For further information or press inquiries, please contact Marc Grossman at
1-800-FAIR-PLAY or visit us at www.thesandersfirm.com or via email at mgrossman(at)thesandersfirm(dot)com.

###


PRWeb eBooks - Another online visibility tool from PRWeb
Contact Information
Marc Grossman
The Sanders Firm
http://www.thesandersfirm.com
1-800-324-7752



Online Web 2.0 Version
You can read the online version of this press release here.

PRWebPodcast Available
Listen to Podcast MP3 Listen to Podcast iTunes Listen to Podcast OGG




                                                                       Page 2/2

If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer
appears here. - PRWeb eBooks - Another online visibility tool from PRWeb

								
To top